S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
NASDAQ:IPA

ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

$1.72
-0.14 (-7.53%)
(As of 02/21/2024 ET)
Today's Range
$1.64
$1.86
50-Day Range
$1.20
$2.41
52-Week Range
$0.94
$4.39
Volume
140,705 shs
Average Volume
92,949 shs
Market Capitalization
$45.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

ImmunoPrecise Antibodies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
365.1% Upside
$8.00 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.32) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.32 out of 5 stars

Medical Sector

626th out of 932 stocks

Pharmaceutical Preparations Industry

291st out of 431 stocks


IPA stock logo

About ImmunoPrecise Antibodies Stock (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPA Stock Price History

IPA Stock News Headlines

My wife was skeptical... until I showed her my account balance.
The Fed just created the single greatest income opportunity I've seen in nearly 20 years. I've put more than $1M of my own money into it. And plan to add another million! I even suggested my wife put her savings into it.    
IPA Announces Proposed Public Offering of Common Shares
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
ImmunoPrecise Antibodies Announces CFO Transition
ImmunoPrecise Antibodies (IPA) Receives a Buy from H.C. Wainwright
IPA Announces Board Refreshment
IPA Responds to 13D Filing
See More Headlines
Receive IPA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/14/2023
Today
2/21/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
4/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IPA
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$9.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+379.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,980,000.00
Pretax Margin
-74.24%

Debt

Sales & Book Value

Annual Sales
$15.61 million
Book Value
$1.74 per share

Miscellaneous

Free Float
24,518,000
Market Cap
$43.95 million
Optionable
Not Optionable
Beta
0.09
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Jennifer Lynne Bath Ph.D.
    CEO, President & Non-Independent Director
  • Dr. Ilse Roodink
    Chief Scientific Officer & Interim General Manager of IPA Europe, Oss
  • Ms. Kristin Taylor CPA
    M.B.A., Chief Financial Officer
  • Mr. David E. Orton
    Chief Operating Officer
  • Dr. Roland Romijn
    Head of General Operations of the Utrecht site of IPA (Europe)














IPA Stock Analysis - Frequently Asked Questions

Should I buy or sell ImmunoPrecise Antibodies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IPA shares.
View IPA analyst ratings
or view top-rated stocks.

What is ImmunoPrecise Antibodies' stock price target for 2024?

2 Wall Street analysts have issued 1-year target prices for ImmunoPrecise Antibodies' shares. Their IPA share price targets range from $7.00 to $9.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 365.1% from the stock's current price.
View analysts price targets for IPA
or view top-rated stocks among Wall Street analysts.

How have IPA shares performed in 2024?

ImmunoPrecise Antibodies' stock was trading at $1.71 at the beginning of 2024. Since then, IPA stock has increased by 0.6% and is now trading at $1.72.
View the best growth stocks for 2024 here
.

Are investors shorting ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 15,300 shares, a decrease of 38.3% from the January 15th total of 24,800 shares. Based on an average daily volume of 110,400 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.1% of the company's shares are short sold.
View ImmunoPrecise Antibodies' Short Interest
.

When is ImmunoPrecise Antibodies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our IPA earnings forecast
.

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) released its earnings results on Thursday, December, 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.02. The company earned $4.50 million during the quarter, compared to the consensus estimate of $4.44 million. ImmunoPrecise Antibodies had a negative net margin of 70.81% and a negative trailing twelve-month return on equity of 28.32%.

Who are ImmunoPrecise Antibodies' major shareholders?

ImmunoPrecise Antibodies' stock is owned by many different retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.87%), Northern Trust Corp (0.23%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPA) was last updated on 2/21/2024 by MarketBeat.com Staff